Ionis Pharmaceuticals (IONS) reported a Q4 net loss Wednesday of $0.66 per diluted share, widening from a loss of $0.06 a year earlier.
Analysts polled by FactSet expected a loss of $1.11.
Revenue for the quarter ended Dec. 31 was $227 million, down from $325 million a year earlier.
Analysts surveyed by FactSet expected $135.3 million.
For the full year, the company said it expects revenue of more than $600 million.
Analysts polled by FactSet expect $666.2 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。